CSSH-1
CSSH-3
CSSH-2

product

more>>

about us

dfgdf

what we do

Hebei Changshan Biochemical Pharmaceutical Co., Ltd. was founded in 2000. On 19 August 2011, the company was listed on the Growth Enterprise Market of Shenzhen Stock Exchange (stock code 300255). The company has four production bases, nine subsidiaries, two overseas companies, and two joint ventures. The company is a biochemical pharmaceutical enterprise, integrating research and development, production, sales, and import and export trade. It is a key high-tech enterprise with products from heparin crude products to low molecular weight heparin injections and a complete heparin industrial chain in the field of heparin, and a leading pharmaceutical company in the production of domestic heparin products.

more>>
Quality policy

Quality of survival, management for efficiency, integrity and reputation, innovation and development.

more>>
  • Always puts the quality at the first place and strictly supervise the product quality of every process.

    Quality

    Always puts the quality at the first place and strictly supervise the product quality of every process.

  • Our Factory has grown into a Premier  Certified manufacturer of High quality, Cost-Effective products

    Certificate

    Our Factory has grown into a Premier Certified manufacturer of High quality, Cost-Effective products

  • The company is a biochemical pharmaceutical enterprise, integrating research and development, production, sales, and import and export trade

    Manufacturer

    The company is a biochemical pharmaceutical enterprise, integrating research and development, production, sales, and import and export trade

Exhibition Style

  • Team 796

    Team

  • Founded Time September 28, 2000

    Founded Time

  • Number of patents 11

    Number of patents

  • Total exports in 2019 68 million dollars

    Total exports in 2019

news

Hebei Changshan Biochemical Pharmaceutical Co., Ltd.

Hebei Changshan Biochemical Pharmaceutical Co., Ltd. was founded in 2000.

Introduction to the new drug-ibenatide

Hebei Changshan Pharmaceutical Co., Ltd. and ConjuChem LLC of the United States signed a joint venture agreement. The two parties jointly established a Sino-foreign joint venture —Changshan Kaijiejian Biopharmaceutical Research and Development (Hebei) Co., Ltd.    With the increasing enr...
more>>

2021 US NCCN guidelines recommend: low molecular weight heparin is the first choice for VTE prevention in hospitalized tumor patients

Malignant tumors are the most important risk factor for venous thrombosis (VTE), and VTE has become the second leading cause of death for tumor patients. Studies have shown that the risk of VTE in cancer patients is at least 4 to 6 times higher than that in non-tumor patients, and VTE increases t...
more>>

[Recruitment of newly-onset type 2 diabetes patients] Recruitment of clinical trial information sharing of newly-onset type 2 diabetes patients Background Information

This study is a randomized, double-blind phase III clinical trial of CJC 1134 PC injection versus placebo initiated by Changshan Kaijiejian Biopharmaceutical Research and Development (Hebei) Co., Ltd. It is planned to enroll 450 patients with type 2 diabetes who have not received diabetes medicat...
more>>

CSBIO Fight the epidemic while speeding up production

The “Recommendations for the Prevention and Treatment of Venous Thromboembolism Related to Novel Coronavirus Pneumonia” pointed out: Nearly 20% of patients with new coronary disease will have coagulation abnormalities, and almost all severe and critical patients have coagulation disor...
more>>

Two misunderstandings of heparin-induced thrombocytopenia

Changshan Medical News Heparin-induced thrombocytopenia (HIT) is a complication characterized by thrombocytopenia caused by heparin, which mainly manifests as thrombocytopenia, platelet activation or thrombosis. There are two clinical types, one is with thrombosis, and the other is only antibody ...
more>>